Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093

Contraception

Volumn 77, Issue 2, 2008, Pages 84-90

  Watts, D Heather ^a   Park, Jeong Gun ^b   Cohn, Susan E ^c   Yu, Song ^b   Hitti, Jane ^d   Stek, Alice ^e   Clax, Pamela A ^f   Muderspach, Laila ^e   Lertora, Juan J L ^g  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f PFIZER INC   (United States)

^g TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiretrovirals; Contraception; Depotmedroxyprogesterone; HIV; Women

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BODY ODOR; CARPAL TUNNEL SYNDROME; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FATIGUE; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MOOD CHANGE; NAUSEA AND VOMITING; NECK PAIN; NEUTROPENIA; OVULATION; SALIVATION DISORDER; SIDE EFFECT; THROMBOCYTE COUNT; VAGINA BLEEDING; VAGINAL DRYNESS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CONTRACEPTIVE AGENTS, FEMALE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; NELFINAVIR; NEVIRAPINE; OVULATION INHIBITION; RNA, VIRAL; SAFETY; VIRAL LOAD;

EID: 38349121002     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.10.002     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. 2005;16:1-46. Also available at: http://www.cdc.gov/hiv/stats/hasrlink.htm.
2. UNAIDS. AIDS epidemic update: December 2005. Available at. http://www.who.int/hiv/epi-update2005_en.pdf
3. Lande R.E. New era for injectables. Popul Rep 23 (1995) 1-32. http://www.infoforhealth.org/pr/online.shtml Available at
4. Lavreys L., Baeten J.M., Kreiss J.K., Richardson B.A., Chohan B.H., Hassan W., et al. Injectable contraceptive use and genital ulcer diseases during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis 189 (2004) 303-311
5. Cohn S.E., Park J.-G., Watts D.H., et al. Depot medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 81 (2007) 222-227
6. Yen-Lieberman B., Brambilla D., Jackson B., et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol. 34 (1996) 2695-2701
7. Calvelli T., Denny T.N., Paxton H., Gelman R., and Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 14 (1993) 702-715
8. Sangi-Haghpeykar H., Poindexter III A.N., Bateman L., and Ditmore J.R. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 88 (1996) 227-233
9. World Health Organization. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting 71 (1993), Bull WHO 677-689
10. World Health Organization. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate: final report. Contraception 28 (1983) 1-20
11. Schwallie P., and Assenzo J. Contraceptive use efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 24 (1973) 331-339
12. Fraser I., and Dennerstein G. Depo-Provera use in an Australian metropolitan practice. Med J Australia 160 (1994) 553-556
13. Westhoff C., Truman C., Kalmuss D., et al. Depressive symptoms and Depo-Provera. Contraception 57 (1998) 237-240
14. Canto De Cetina T.E., Canto P., and Luna M.O. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 63 (2001) 143-146
15. Hubacher D., Goco N., Gonzalez B., and Taylor D. Factors affecting continuation rates of DMPA. Contraception 60 (2000) 345-351
16. Westfall J.M., Main D.S., and Barnard L. Continuation rates among injectable contraceptive users. Fam Plan Perspect 28 (1996) 275-277
17. Potter L.S., Dalberth B.T., Canamar R., and Betz M. Depot medroxyprogesterone acetate pioneers: a retrospective study at a North Carolina health department. Contraception 56 (1997) 305-312
18. Lavreys L., Baeten J.M., Martin Jr. H.L., et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 18 (2004) 695-697
19. Saada M., Le Chenadec J., Berrebi A., et al. Pregnancy and progression to AIDS: results of the French prospective cohorts. AIDS 14 (2000) 2355-2360
20. Weisser M., Rudin C., Battegay M., Pfluger D., Kully C., and Egger M. Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies. J Acquir Immune Defic Syndr Hum Retrovirol 15 (1998) 404-410
21. Cejtin H.E., Jacobson L., Springer G., et al. Effect of hormonal contraceptive use on plasma HIV-1 RNA levels among HIV-infected women. AIDS 17 (2003) 1702-1704
22. Efavirenz package insert, available at http://www.bms.com/cgi-bin/anybin.pl?sql=select+PPI+from+TB_PRODUCT_PPI+where+PPI_SEQ=94&key=PPI. Accessed on 1/17/2007.
23. Clark M.K., Dillon J.S., Sowers M., and Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Internat J Obesity 29 (2005) 1252-1258
24. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13 (2002) 581-587
25. Clark M.K., Sowers M.F., Nichols S., and Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 82 (2004) 1580-1586
26. Dolan S.E., Huang J.S., Killilea K.M., Sullivan M.P., Aliabadi N., and Grinspoon S. Reduced bone density in HIV-infected women. AIDS 18 (2004) 475-483
27. Study of fat redistribution and metabolic changes in HIV infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 42 (2006) 562-571